Therapeutic compounds and uses thereof
Described herein are compounds of Formula (I) or Formula (VI), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I) or Formula (VI) and pharmaceutical compositions thereof that are mucus penetrating. Methods of using the compounds or pharmaceutical compositions thereof for treating diseases are also provided.
1. A compound of Formula (I):
or a pharmaceutically acceptable salt thereof,
wherein:
R 1 is H or C 1-6 alkyl;
R 2 is:
(1) heterocyclyl, provided that the heterocyclyl is not tetrahydropyranyl, if X is —O—; or
(2) optionally substituted oxetanyl, or optionally substituted spiro bicyclic heterocyclyl wherein one or two atoms in the heterocyclic ring are independently O or N, when X is a bond, —O—, or —C(═O)—;
each instance of R 3 is independently H, F, Cl, Br, I, CN, or OH;
Z is optionally substituted aliphatic, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted quinolyl;
m is 0, 1, 2, 3, or 4; and
n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
2. The compound of claim 1 , wherein m is 0.
3. The compound of claim 1 , wherein m is 1 and R 3 is Cl.
4. The compound of claim 1 , wherein m is 1 and R 3 is F.
5. The pharmaceutical composition of claim 1 , wherein R 1 is CH 3 .
6. The pharmaceutical composition of claim 1 , wherein Z is optionally substituted isooxazolyl.
7. The pharmaceutical composition of claim 1 , wherein Z is optionally substituted phenyl.
8. The pharmaceutical composition of claim 1 , wherein Z is:
wherein e, f, and h are independently 1, 2, or 3.
9. The pharmaceutical composition of claim 1 , wherein Z is C 1-6 alkyl.
10. The pharmaceutical composition of claim 1 , wherein Z is optionally substituted thiophenyl.
11. The pharmaceutical composition of claim 1 , wherein X is a bond.
12. The pharmaceutical composition of claim 1 , wherein X is —O—.
13. The pharmaceutical composition of claim 1 , wherein X is —C(═O)—.
14. The pharmaceutical composition of claim 1 , wherein n is 1.
15. The pharmaceutical composition of claim 1 , wherein n is 2.
16. The pharmaceutical composition of claim 1 , wherein R 2 is:
wherein p and q are independently 0, 1, 2, 3, or 4.
17. The pharmaceutical composition of claim 1 , wherein R 2 is:
wherein p, q, s, and t are independently 0, 1, 2, 3, or 4.
18. The compound of claim 1 , which is:
19. A method of treating an ocular disease comprising administering a compound according to claim 1 to a subject in need thereof.
20. The method of claim 19 , wherein the ocular disease is a retinopathy, age-related macular degeneration, or glaucoma.
21. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
22. The pharmaceutical composition of claim 21 , wherein the pharmaceutical composition is suitable for administration to an eye.
23. A compound of Formula (VI):
or a pharmaceutically acceptable salt thereof,
wherein:
R 1 is H or optionally substituted C 1-6 alkyl;
R 2 is heterocyclyl;
X is a bond, —O—, or —C(═O)—;
each instance of R 3 is independently H, F, Cl, Br, I, CN, or OH;
Y is CH;
Z is optionally substituted aliphatic, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted quinolyl;
m is independently 0, 1, 2, 3, or 4; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
24. A method of treating an ocular disease comprising administering a compound according to claim 23 to a subject in need thereof.
25. The method of claim 24 , wherein the ocular disease is a retinopathy, age-related macular degeneration, or glaucoma.
26. A pharmaceutical composition comprising a compound of claim 23 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.